Novan, Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for filing Novan's New Drug Application (NDA) seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum (molluscum). The Company also received its Prescription Drug User Fee (PDUFA) goal date of January 5, 2024.
1st Jan change | Capi. | |
---|---|---|
+180.51% | 8.67B | |
+2.29% | 983M | |
+41.91% | 883M | |
+26.17% | 825M | |
+1.92% | 665M | |
+9.52% | 664M | |
-.--% | 600M | |
+9.17% | 530M | |
-.--% | 500M |